Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-advanced or Metastatic Triple-Negative Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Category & Conditions: Cancer
Medicine: Ladiratuzumab Vedotin (LV; SGN-LIV1A)
ClinicalTrials.gov Identifier (NCT): NCT03310957
Protocol ID: C5741001/SGNLVA-002
Open Plain Language Summary Result:
Click here